Ablynx has achieved an initial discovery milestone with a multi-specific Nanobody construct as part of its collaboration with Novo Nordisk, triggering a €1 million payment to Ablynx. Under the terms of the agreement, entered November 2015, Ablynx received an upfront license fee of €5 million and will receive as much as €4 million in research funding during the initial three-year research term. Ablynx is also eligible to receive potential development, regulatory and commercial milestones of as...